Cullinan Therapeutics (CGEM) Gains from Investment Securities (2020 - 2023)
Historic Gains from Investment Securities for Cullinan Therapeutics (CGEM) over the last 4 years, with Q4 2023 value amounting to -$9.1 million.
- Cullinan Therapeutics' Gains from Investment Securities fell 27514.85% to -$9.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$4.4 million, marking a year-over-year decrease of 11172.72%. This contributed to the annual value of $10.4 million for FY2024, which is 33460.41% up from last year.
- According to the latest figures from Q4 2023, Cullinan Therapeutics' Gains from Investment Securities is -$9.1 million, which was down 27514.85% from $4.6 million recorded in Q2 2023.
- In the past 5 years, Cullinan Therapeutics' Gains from Investment Securities ranged from a high of $32.7 million in Q3 2022 and a low of -$9.1 million during Q4 2023
- Over the past 4 years, Cullinan Therapeutics' median Gains from Investment Securities value was $4.6 million (recorded in 2020), while the average stood at $5.2 million.
- The largest annual percentage gain for Cullinan Therapeutics' Gains from Investment Securities in the last 5 years was 363664.12% (2023), contrasted with its biggest fall of 27514.85% (2023).
- Cullinan Therapeutics' Gains from Investment Securities (Quarter) stood at $4.6 million in 2020, then surged by 131.79% to $10.7 million in 2021, then crashed by 51.22% to $5.2 million in 2022, then tumbled by 275.15% to -$9.1 million in 2023.
- Its Gains from Investment Securities stands at -$9.1 million for Q4 2023, versus $4.6 million for Q2 2023 and $75000.0 for Q1 2023.